NAGIOS: RODERIC FUNCIONANDO

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.

dc.contributor.author	Piñana, José Luis
dc.contributor.author	López-Corral, Lucia
dc.contributor.author	Martino, Rodrigo
dc.contributor.author	Vázquez, Lourdes
dc.contributor.author	Pérez, Ariafna
dc.contributor.author	Martin-Martin, Gabriel Andrés
dc.contributor.author	Gago, Beatriz
dc.contributor.author	Sanz-Linares, Gabriela
dc.contributor.author	Sanchez-Salinas, Andrés
dc.contributor.author	Villalon, Lucia
dc.contributor.author	Conesa, Venancio
dc.contributor.author	Olave, Maria T.
dc.contributor.author	Corona, Magdalena
dc.contributor.author	Marcos Corrales, Sara
dc.contributor.author	Tormo Diaz, Mar
dc.contributor.author	Hernández-Rivas, Jose Ángel
dc.contributor.author	Montoro, Juan
dc.contributor.author	Rodriguez-Fernandez, Alicia
dc.contributor.author	Risco Gálvez, Irene
dc.contributor.author	Rodríguez-Belenguer, Pablo
dc.contributor.author	Hernandez-Boluda, Juan Carlos
dc.contributor.author	García-Cadenas, Irene
dc.contributor.author	Ruiz-García, Montserrat
dc.contributor.author	Muñoz-Bellido, Juan Luis
dc.contributor.author	Solano Vercet, Carlos
dc.contributor.author	Cedillo, Ángel
dc.contributor.author	Sureda, Anna
dc.contributor.author	Navarro Ortega, David
dc.contributor.author	Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation
dc.date.accessioned	2022-06-13T08:40:55Z
dc.date.available	2022-06-13T08:40:55Z
dc.date.issued	2022
dc.identifier.citation	Piñana, Jose Luis López-Corral, Lucia Martino, Rodrigo Vázquez, Lourdes Pérez, Ariafna Martin-Martin, Gabriel Andrés Gago, Beatriz Sanz-Linares, Gabriela Sanchez-Salinas, Andrés Villalon, Lucia Conesa, Venancio Olave, Maria T. Corona, Magdalena Marcos Corrales, Sara Tormo Diaz, Mar Hernández-Rivas, Jose Ángel Montoro, Juan Rodriguez-Fernandez, Alicia Risco Gálvez, Irene Rodríguez-Belenguer, Pablo Hernandez-Boluda, Juan Carlos García-Cadenas, Irene Ruiz-García, Montserrat Muñoz-Bellido, Juan Luis Solano Vercet, Carlos Cedillo, Ángel Sureda, Anna Navarro Ortega, David Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation 2022 SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal Of Hematology & Oncology 15 1 54
dc.identifier.uri	https://hdl.handle.net/10550/83104
dc.description.abstract	Background The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3-6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. Results At a median follow-up of 165 days after complete immunization, 37 out of 1394 (2.6%) developed breakthrough SARS-CoV-2 infection at median of 77 days (range 7-195) after full vaccination. The incidence rate was 6.39 per 100 persons-year. Most patients were asymptomatic (19/37, 51.4%), whereas only 19% developed pneumonia. The mortality rate was 8%. Lack of detectable antibodies at 3-6 weeks after full vaccination was the only variable associated with breakthrough infection in multivariate logistic regression analysis (Odds Ratio 2.35, 95% confidence interval 1.2-4.6, p = 0.012). Median antibody titers were lower in cases than in non-cases [1.83 binding antibody units (BAU)/mL (range 0-4854.93) vs 730.81 BAU/mL (range 0-56,800), respectively (p = 0.007)]. We identified 250 BAU/mL as a cutoff above which incidence and severity of the infection were significantly lower. Conclusions Our study highlights the benefit of developing an antibody response in these highly immunosuppressed patients. Level of antibody titers at 3 to 6 weeks after 2-dose vaccination links with protection against both breakthrough infection and severe disease for non-Omicron SARS-CoV-2 variants.
dc.language.iso	eng
dc.relation.ispartof	Journal Of Hematology & Oncology, 2022, vol. 15, num. 1, p. 54
dc.subject	Virus
dc.title	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.
dc.type	journal article	es_ES
dc.date.updated	2022-06-13T08:40:56Z
dc.identifier.doi	10.1186/s13045-022-01275-7
dc.identifier.idgrec	154049
dc.rights.accessRights	open access	es_ES